Brian Druker is an Oncology physician. ClinicalTrials.gov lists 4 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
3181 SW Sam Jackson Park Rd, L952
Portland, OR 97239
Telephone
503-494-5596Registry record last updated 8 Jul 2007.
Clinical trials
- Selumetinib and Paclitaxel as Second-Line Treatment in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer
Sponsor: OHSU Knight Cancer Institute
- Imatinib Mesylate or Dasatinib in Treating Patients With Previously Untreated Chronic Phase Chronic Myelogenous Leukemia
Sponsor: National Cancer Institute (NCI)
- Imatinib Mesylate Plus Cytarabine in Treating Patients With Chronic Myelogenous Leukemia
Sponsor: OHSU Knight Cancer Institute
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
7 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Amgen Inc.Program year202554 payments$555,495openpaymentsdata.cms.gov ↗
- Blueprint Medicines CorporationProgram year20254 payments$17,794openpaymentsdata.cms.gov ↗
- GENZYME CORPORATIONProgram year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
NIH funding
11 NIH research awards on record, funded 1993–2026 per NIH RePORTER. The latest:
- Architecture and Trajectory of Acquired Resistance to Therapy in AML
Oregon Health & Science University
FY2026$1,308,997U54CA224019 - Proteogenomic characterization of early and late resistance mechanisms in acute myeloid leukemia
Oregon Health & Science University
FY2026$1,168,036U01CA271412 - Translating Improved Pairing and Timing of Drug Combination Strategies
Oregon Health & Science University
FY2026$302,354U54CA224019
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
Freddie Bray
Centre National de la Recherche Scientifique
Jacques Ferlay
Centre international de recherche sur le cancer
Hermann Brenner
German Cancer Research Center
Isabelle Soerjomataram
Centre international de recherche sur le cancer
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”